Screener
Taysha Gene Therapies, Inc. TSHA Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Taysha Gene Therapies, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026. Open the filing →
- Filed
- May 6, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-207666
FAQ
- What is Taysha Gene Therapies, Inc.'s debt-to-equity?
- Taysha Gene Therapies, Inc. (TSHA) reported debt-to-equity of 0.3× in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s debt-to-equity changed year-over-year?
- Taysha Gene Therapies, Inc.'s debt-to-equity decreased by 71.1% year-over-year, from 1.1× to 0.3×.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s debt-to-equity?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s debt-to-equity has grown at a -7.6% compound annual growth rate (CAGR), from 0.4× to 0.3×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Taysha Gene Therapies, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude